研究动态
Articles below are published ahead of final publication in an issue. Please cite articles in the following format: authors, (year), title, journal, DOI.

在进展期铂类耐药性复发上皮性卵巢癌的治疗效果观察中,观察阿帕替尼的疗效。

Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer.

发表日期:2023 Feb 23
作者: Zhongmian Pan, Zhongbin Luo, Hongying He, Yujie Chen, Bingbing Zhao, Zhijun Yang, Li Li
来源: Journal of Ovarian Research

摘要:

阿帕替尼是一种口服抗血管生成药物,主要靶向血管内皮生长因子受体2(VEGFR-2),广泛用于各种实体肿瘤的治疗。本研究旨在评估阿帕替尼在晚期顽固性经铂复发上皮性卵巢癌(EOC)患者中的临床疗效和安全性。进行了回顾性分析,收集了2014年1月至2018年5月期间IIIC-IV期经铂复发的EOC患者的临床数据。对客观缓解率(ORR),疾病控制率(DCR),无进展生存期(PFS)和总生存期(OS)进行了回顾和评估。使用倾向性评分匹配(PSM)方法确定本研究包括的最终病例数据。根据1:2倾向性匹配,最终考虑了108名患者:阿帕替尼组36名,对照组72名。随访于2019年1月结束,中位随访时间为28个月。在阿帕替尼组中,ORR为30.56%,DCR为66.67%,而在对照组中,ORR为16.67%,DCR为44.44%。在阿帕替尼组中,中位PFS为6.0个月(95%CI 3.69-8.31),中位OS为15.8个月(95%CI 6.99-24.6),而在对照组中,中位PFS为3.3个月(95%CI 2.44-4.16),中位OS为9.2个月(95%CI 6.3-12.06);差异具有统计学意义(P <0.05)。阿帕替尼在减少PFS [HR 0.40(95%CI 0.22-0.76),P = 0.0017]和OS [HR 0.40(95%CI 0.21-0.73),P = 0.002]的风险方面比常规化疗更有效。多元Cox分析显示,治疗周期和血清CA125水平下降是患者PFS的独立危险因素,而阿帕替尼,治疗周期的长度和病变部位是影响患者OS的独立危险因素。阿帕替尼组的主要3-4级不良事件是高血压,手足综合征和口腔粘膜溃疡,所有不良事件都可控制。阿帕替尼在晚期顽固性经铂复发EOC患者中被证明是安全和有效的。应开展更深入的临床研究和应用。 © 2023. 作者(们)
Apatinib is an oral anti-angiogenic drug that mainly targets vascular endothelial growth factor receptor 2 (VEGFR-2) and is widely used in a variety of solid tumours. The purpose of this study is to evaluate the clinical efficacy and safety of apatinib in patients with advanced platinum-resistant relapsed epithelial ovarian cancer (EOC).A retrospective analysis was performed, the clinical data of patients with stage IIIC-IV platinum-resistant relapsed EOC between January 2014 and May 2018 were collected. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were reviewed and evaluated. The propensity score matching (PSM) method was used to determine the final case data included in this study.According to 1:2 propensity matching, 108 patients were finally taken into account: 36 in the apatinib group and 72 in the control group. The follow-up ended in January 2019, and the median follow-up time was 28 months. In the apatinib group, ORR was 30.56% and DCR was 66.67%, whereas in the control group, ORR was 16.67% and DCR was 44.44%. In the apatinib group, median PFS was 6.0 months (95% CI 3.69-8.31) and median OS was 15.8 months (95% CI 6.99-24.6), while in the control group, median PFS was 3.3 months (95% CI 2.44-4.16) and median OS was 9.2 months (95% CI 6.3-12.06); the difference was statistically significant (P < 0.05). Apatinib was more effective than conventional chemotherapy in reducing the risk of PFS [HR 0.40 (95% CI 0.22-0.76), P = 0.0017] and OS [HR 0.40 (95% CI 0.21-0.73), P = 0.002]. Multivariate Cox analysis showed that the course of treatment and decrease in serum CA125 levels are independent risk factors for PFS in patients, while apatinib, the length of treatment course and the location of the lesion are independent risk factors for recurrence affecting the OS of patients. The main grade 3-4 adverse events in the apatinib group were hypertension, hand-foot syndrome, and oral mucosal ulcers, and all adverse events were controllable.Apatinib was found to be both safe and effective in patients with advanced platinum-resistant relapsed EOC. More in-depth clinical research and applications should be carried out.© 2023. The Author(s).